Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management.

Abstract

Recombinant interferon alfa (r-IFN alpha 2) has been shown to normalize the aminotransferase levels in approximately 50% of patients with chronic hepatitis C virus (HCV). Few patients experience a relapse during the treatment, in spite of a complete initial response (breakthrough). We studied 191 HCV Ab-positive patients with histologically proven chronic hepatitis. All of them were treated with r-IFN alpha 2 (3 MU three times a week). A complete response was seen in 54.4%. However, 12 of 104 responders experienced a breakthrough. At the time of breakthrough, neutralizing IFN antibodies were positive in 6 of 12 patients. Binding IFN antibodies were positive in all of these 12 patients. Continued treatment with r-IFN alpha 2, even at higher doses, did not restore the previous response in any patient. All of them were then switched to natural lymphoblastoid IFN, and this rapidly restored a complete response in all of the patients.

• Authors: L Roffi, G C Mels, G Antonelli, G Bellati, F Panizzuti, A Piperno, M Pozzi, D Ravizza, G Angeli, F Dianzani
• Journal: Hepatology (Baltimore, Md.) (Hepatology) Vol. 21 Issue 3 Pg. 645-9 (Mar 1995) ISSN: 0270-9139 [Print] United States
• PMID: 7875661 (Publication Type: Journal Article)

Chemical References

• Antibodies
• Interferon-alpha
• Recombinant Proteins
• Alanine Transaminase

Topics

• Adolescent
• Adult
• Aged
• Alanine Transaminase (blood)
• Antibodies (analysis)
• Chronic Disease
• Female
• Hepatitis C (blood, epidemiology, therapy)
• Humans
• Interferon-alpha (immunology, therapeutic use)
• Male
• Middle Aged
• Prevalence
• Recombinant Proteins
• Recurrence
• Treatment Outcome